Clinical Trial

ctDNA in Cutaneous Squamous Cell Carcinoma

Recruiting
View on ClinicalTrials.gov →
Summary
The purpose of this study is to test the potential for a liquid biopsy assay to detect residual disease after surgery in patients with cutaneous squamous cell carcinoma as well as the potential for this assay to monitor response to immunotherapy treatment.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2025-03-12; most recent amendment 2026-03-26.
Status change: Not Yet Recruiting → Recruiting 2025-03-24
Trial Details
NCT Number NCT06875609
Lead Sponsor Massachusetts Eye and Ear Infirmary
Collaborators: Haystack Oncology, Inc., Massachusetts General Hospital
Conditions Cutaneous Squamous Cell Carcinoma
Enrollment 60 participants
Start Date 2025-03-24
Primary Completion 2028-04-30 (estimated)
Study Completion 2029-04-30 (estimated)
Updated on ClinicalTrials.gov 2026-03-30